<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJOC</journal-id><journal-title-group><journal-title>International Journal of Organic Chemistry</journal-title></journal-title-group><issn pub-type="epub">2161-4687</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijoc.2014.44028</article-id><article-id pub-id-type="publisher-id">IJOC-52328</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject><subject> Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Synthesis of Novel Fluorine Substituted Isolated and Fused Heterobicyclic Nitrogen Systems Bearing 6-(2’-Phosphorylanilido)-1,2,4-Triazin-5-One Moiety as Potential Inhibitor towards HIV-1 Activity
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>eda</surname><given-names>M. Abdel-Rahman</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohammed</surname><given-names>S. T. Makki</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Abeer</surname><given-names>N. Al-Romaizan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Chemistry, Faculty of Science, King Abdul Aziz University, Jeddah, KSA</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>ar-orkied@hotmail.com(ANA)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>11</month><year>2014</year></pub-date><volume>04</volume><issue>04</issue><fpage>247</fpage><lpage>268</lpage><history><date date-type="received"><day>13</day>	<month>September</month>	<year>2014</year></date><date date-type="rev-recd"><day>29</day>	<month>October</month>	<year>2014</year>	</date><date date-type="accepted"><day>14</day>	<month>November</month>	<year>2014</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Novel 6-(5’-fluoro-2’-diphenylphosphorylanilido)-3-hydrazino-1,2,4-trizin-5 (2H) one (3) is achieved from hydrozinolysis of the corresponding 3-thioxo-analoges 2. Compound 2 is also obtained from phosphorylation of 6-(5’-fluoro-2’-aminophenyl)-3-thioxo-1,2,4-triazin-5(2H) one (1). Novel fluorine substituted isolated and/or fused heterobicyclic nitrogen systems bearing and/or containing, 6-phosphoryl anilido-1,2,4-trizin-5 (2H) one moiety (4 - 22) have been synthesized from ring closure reactions of compound 3 with π-acceptors activated carbon compounds in different medium and conditions. Structures of the products are characterized by MS, IR, UV-VIS, CH, N, and 1H/13CNMR spectral data. The new products have been evaluated as potential inhibitors towards HIV-1 activity.
 
</p></abstract><kwd-group><kwd>Synthesis</kwd><kwd> Fluorine</kwd><kwd> Phosphorus</kwd><kwd> Sulfar 1</kwd><kwd>2</kwd><kwd>4-Trizinones HIV-1</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Organophosphorus systems are ubiquitous in nature and exhibit many applications in the field of agriculture medicine and industry [<xref ref-type="bibr" rid="scirp.52328-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.52328-ref2">2</xref>] . Many multi-ring phosphorus heterocycles are used as pesticide [<xref ref-type="bibr" rid="scirp.52328-ref3">3</xref>] , bactericide [<xref ref-type="bibr" rid="scirp.52328-ref4">4</xref>] -[<xref ref-type="bibr" rid="scirp.52328-ref6">6</xref>] , antibiotics [<xref ref-type="bibr" rid="scirp.52328-ref4">4</xref>] , and acts as HIV protease inhibitors [<xref ref-type="bibr" rid="scirp.52328-ref7">7</xref>] . Thus, synthesis of new phosphorus bearing a heterocycles has attracted the attention of researchers. Phosphorylation of organic compounds often improves their biological activity, especially through a vital energy, because the P-O is the store of energy for metabolism process. For example, phophorylated-N in the nucleocapsid affects the interaction between the N-atom and the genomic RNA. The charge repulsion between the negatively charged phosphoserine and the negatively charged RNA may weaken the interaction between N-atom and RNA, thus enabling the viral polymerase to gain access to genomic RNA and to initiate viral RNA transcription and replication [<xref ref-type="bibr" rid="scirp.52328-ref8">8</xref>] . On the other hand, chemistry of N-phosphorylheterocycles showed that these compounds from two dimensional polymeric chains via intermolecular P-O<sup>−+</sup>H-N hydrogen bonds [<xref ref-type="bibr" rid="scirp.52328-ref9">9</xref>] . Also, phosphodiester compound had a type of action, especially enzymetic of DNA replication [<xref ref-type="bibr" rid="scirp.52328-ref10">10</xref>] on DNA ligase as (<xref ref-type="fig" rid="fig1">Figure 1</xref>(.</p><p>It is interesting that fluorine containing aheterocycles bearing functional groups exhibits highly effective in biological process, pharmaceuticals, agrochemicals, polymers and a wide range of consumer products [<xref ref-type="bibr" rid="scirp.52328-ref11">11</xref>] . It reflects its resistance to metabolic change due to the strength of the C-F bond providing biological stability and the application of its nonstick-interfacial physical characteristics [<xref ref-type="bibr" rid="scirp.52328-ref12">12</xref>] -[<xref ref-type="bibr" rid="scirp.52328-ref16">16</xref>] . Abdel-Rahman et al. [<xref ref-type="bibr" rid="scirp.52328-ref17">17</xref>] -[<xref ref-type="bibr" rid="scirp.52328-ref21">21</xref>] reported the synthesis and chemical reactivity of 3-thioxo-1,2,4-triazin-5 one derivatives as a bioactive molecules, especially as anti-cancer, anti-AIDS, Amyllolytic, cellobiase and antimicrobial agents. Based upon these observations, the aim of this work is to study the formation of 6-(5’-fluoro-2’-phosphoryl anilido-3-hydrazino-1,2,4- triazin-5 (2H) one then study their behaviour as electron donor towards different electron acceptors such as carbo-sulfur, oxygen, halogen and nitrogen compounds; finally, a type of isolated and/or fused heterobicyclic systems obtained and evaluation as potential inhibitors towards HIV-1 virus.</p></sec><sec id="s2"><title>2. Experimental</title><p>Melting points were determined with an electro-thermal Bibbly Stuart Scientific Melting point SMPI (UK). A perkin Elmer (Lambda EZ-2101) double beam spectrophotometer (190 - 1100 nm) used for recording the electronic spectra. A Perkin Elmer model RXI-FT-IR 55,529 cm<sup>−1</sup> used for recording the IR spectra (EtOH as solvents). A Brucker advance DPX 400 MHz using TMS as an internal standard for recording the <sup>1</sup>H/<sup>13</sup>C NMR spectra in deuterated DMSO (δ in pp m). AGC- MS-QP 1000 Ex model is used for recording the mass spectra. Hexafluorobenzene was used as external standard for <sup>19</sup>FNMR at 84.25 MHz and <sup>31</sup>P (in CDCl<sub>3</sub>, 101.25 MHZ).</p><p>Elemental analysis was performed on Micro analytical Center of National Reaches Center-Dokki, Cairo, Egypt. Compound 1 prepared according the reported method [<xref ref-type="bibr" rid="scirp.52328-ref17">17</xref>] .</p><p>6-(2’-aminos-5’-fluorophenyl-3-thioxo-1,2,4-triazin-5(2H)one (1)</p><p>A mixture of 5-fluoroisatin (0.01 mol) in sodium hydroxide solution (5%, 50 ml) warm for 10 min, then thiosemicarbazide (0.01 mol, in hot water, 10 ml) add and complete the refluxing for 2 h. The reaction mixture cooled then poured onto ice and neutralize with diluted HCl. The solid thus obtained filtered off and crystallized from ethanol to give 1 as yellow crystals, yield 80%; m.p. 265˚C. Analytical data; found: C, 44.91; H, 2.90; F, 7.58: N, 23.40; S, 13.29%.Calculated for C<sub>9</sub>H<sub>7</sub>FN<sub>4</sub>OS (238); C, 45.37; H, 2.94; F, 7.98; N, 23.52; S, 13.44%.UV: λ<sub>max</sub> (EtOH) = 280 nm. IR νcm<sup>−1</sup>: 3424(NH<sub>2</sub>), 3258, 3169 (NH, NH), 1685 (C=O), 1618 (deform. NH<sub>2</sub>), 1545 (C=N), 1263 (C-F), 858,818 (aryl CH), 685 (C-F). <sup>1</sup>H NMR (DMSO) δ = 14.66, 12.66, 10.90 (each s, 1H, 3NH), 8.68 - 8.06, 7.69 - 7.64, 7.39 - 7.30, (s, 3H, aryl protons). <sup>13</sup>C NMR (DMSO): δ 179.47(C=S), 162 (C=O), 159 - 157 (C-F), 138.54 (C=N), 131.82, 121.8, 121.51 (aromatic carbons, 78.14, 77.71 (C<sub>5 </sub>- C<sub>6</sub>, 1,2,4-trinzine). M/Z (Int. %); 256 (M + H<sub>2</sub>O, 5%), 68 (100), 148(21), 138(18), 110 (30), 96 (50), 82(58.0), 70(78).</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> The reaction of DNA ligase phospho diester link</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x6.png"/></fig><p>6-(5’-Fluoro-2’-diphenylphosphorylanilido)-3-thioxo-1,2,4-triazin-5(2H)one (2)</p><p>Equimolar mixture of compound 1 and diphenylphosphoryl chloride in DMF (20 ml) warm for 1h, cooled then poured onto ice. The produce solid filter off and crystallized from methanol to give 2 as deep yellow crystals. Yield 70%; m.p. 218-220˚C. Analytical data; found: C, 53.39; H, 3.51; F, 3.88: N, 11.69%.Calculated for C<sub>21</sub>H<sub>16</sub>FN<sub>4</sub>PSO<sub>4</sub>(470); C, 53.61; H, 3.70; F, 4.04; N, 11.91%. IR νcm<sup>−1</sup>: 3133.8 (NH), 1688.4 (C=O), 1574 (C=N), 1370 (Cyclic NCSN), 1262 (C-F), 1200 (P=O), 1150 (C-S), 10.96 (Ph-O-P), 858, 801 (substituted phenyls) M/Z: (Int.%); 473 (M + 3, 5.11), 110 (100).</p><p>3-Hydrazino-6-(5’-fluoro-2’-diphenylphosphorylanilido)-1,2,4-triazin-5(2H)one (3)</p><p>A mixture of compound 2 (1 gm) and hydrazine hydrate (2ml) in ethanol (50ml) reflux for 2h. cooled. The solid thus produce filter off and crystallized from ethanol to give 3 as orange crystals, yield 85%; m.p. 178˚C - 180˚C. Analytical data; found: C, 53.45; H, 3.59; F, 3.80%.Calculated for C<sub>21</sub>H<sub>18</sub>FN<sub>6</sub>PO<sub>4</sub>(468), C, 53.84; H, 3.84; F, 4.02; N, 17.14%. IR ν cm<sup>−1</sup> = 3381, 3340, 3220 - 3190 (NH, NH, NH<sub>2</sub>), 1682 (C=O), 1558 (C=N), 1266.9 (C-F), 1210-1156 (P=O). 1050 (Ph-O-P), 860,805 (substituted phenyls).<sup>1</sup>H NMR(DMSO) δ = 10.7, 10.2, 8.7 (each s, 3H, 3NH, 1,2,4-triazino NH-P=O), 7.511, 7.27-2.24, 7.23-7.22 (each s, 3H, aryl protons); 7.143 - 7.002; 6.860 - 6.796 (each m, 10H, phenyl protons), 2.88 (s, 2H, NH<sub>2</sub> of hydrazine), <sup>13</sup>C NMR (DMSO) δ = 163.78, 159.44, 157.86, 134.97, 129.07, 127.65, 123.66, 122.87, 120.12, 120.09, 113.47, 113.31, 110.77, 110.71, 107.93, 105.27, 105.10, 77.76, 77.33.</p><p>3-(3’-Amino-4’-carboxy-5-(4-chlorophenyl)-4’,5’-dihydro-pyrazolin-1’-yl)-6-(5’-fluoro-2’-diphenylphosph- orylanilido)-1,2,4-triazin-5(2H)one (4)</p><p>Equimolar amounts of 3 and α-(4-chlorophenylidene) cyano acetic acid in ethanol (100 ml) and a few drops piperidine (0.5 ml) reflux for 8h, cooled, then added off and crystallized from dioxan to give 4 as yellowish crystals, yield 65% m.p., 158˚C - 160˚C. Analytical data; found: C, 54.81; H, 3.11; F, 2.55; Cl, 5.09; N, 14.29%. Calculated for C<sub>31</sub>H<sub>24</sub>FClN<sub>7</sub>PO<sub>6</sub>(675). C, 55.11; H, 3.55; F, 2.81; Cl, 5.18; N, 14.51%; M/S: 675 (1.11), 95(100). IR νcm<sup>−1</sup>: 3420 (OH), 3381, 3155 (NH, NH<sub>2</sub>), 1680 (C=O) 1558(C=N), 1478 (deform aliphatic CH), 1269 (C-F), 1200 (P=O), 1043 (Ph-O-P), 993.861, 804 (Aryl CH).<sup>1</sup>H NMR (DMSO) δ = 10.67, 10.14, 8.72 (each δ, 3H, 3NH, 1,2,4-triazinare NH-P=O), 9.77 (δ, 1H, OH), 8.15 - 7.52, 7.36 - 7.29, 7.13 - 7.00, 6.991 - 6.811 (each m, 19H, 7H aryl, 10H phenyls pyrazole protons); 3.46 (δ, 2H, NH<sub>2</sub>).<sup>13</sup>C NMR (DMSO) δ: 179.64; 163.76; 163.05; 159.42; 157.84; 138.58; 134.94; 128.65; 127.59; 123.72; 123.66; 121.13; 121.07; 117.67; 117.51; 113.45; 113.28; 112.06; 112.01; 110.75; 110.70; 109.66; 108.09; 107.92; 105.25; 105.08; 77.78; 77.35; 23.64.</p><p>3-(3’-Methyl-5’-arylamino-pyrazolin-1’-yl)-6(5’-fluoro-2’-diphenylphosphorylanilido)-1,2,4-trinzin-5(2H) one (5)</p><p>A mixture of 3 (0.01 mol) and acetyl acetanilide derivative (0.01 mol) in DMF (50 ml) reflux for 2h, cooled then poured onto ice. The solid thus yield filtere off and crystallized from dioxan to give 5 as deep-yellowish crystals, yield 70%; m.p. 100˚C - 101˚C. Analytical data; found C, 56.03; H, 3.41; F, 2.23; N, 16.17; S, 3.91%. Calculated for C<sub>36</sub>H<sub>29</sub>FN<sub>9</sub>PSO<sub>6</sub>(765). C, 56.47; H, 3.79; F, 2.48; N, 16.47; S, 4.18%. IR νcm<sup>−1</sup>: 3424, 3220 - 31.70 (NH, NH), 2932 (CH<sub>3</sub>), 1694 (C=O), 1620 (C=N), 1358 (SO<sub>2</sub>-NH), 1268 (C-F), 1220 (P=O), 1054 (Ph-O-P), 952, 909, 810, 758 (aryl CH).<sup>1</sup>H NMR (DMSO) δ = 12.28, 12.27, 10.36, 10.21 (each s, 4H, 4NH) 9.7 (s, 1H, C<sub>4</sub>- of pyrazole), 7.979, 7.971, 7.556, 7.545 (m, 4-H of pyridine); 7.34, 7.336, 7.322, 7.091(m, 4H of aryl-P-SO<sub>2</sub>NH) 6.95 - 6.83; 6.66 - 6.52; 6.41 - 6.16 (each m, 13H of FC<sub>6</sub>H<sub>3</sub>, 2C<sub>6</sub>H<sub>5</sub>). 0.46 - 0.45 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR(DMSO) δ = 179.64, 163.75, 163.03, 162.41, 158.08, 157.99, 157.47; 151.97; 138.58, 134.94, 130.23, 129.10, 123.72, 123.66, 117.66, 117.50, 115.11, 113.41, 113.25, 112.97, 112.07, 112.02, 110.76, 110.71, 108.09, 107.92, 105.21, 105.04, 77.83-77.40, 36.40, 31.29.</p><p>3-(3’-Amino-4’,5’-dihydro-5’-oxo-pyrazolin-1’-yl)-6(5’-fluoro-2’-diphenylphosphorylanilido)-1,2,4-triazin- 5(2H)one (6)</p><p>Equiomolar of 3 and ethyl cyanoacetate in THF (100ml) reflux for 4H, cooled. The solid thus produce filtered off and crystallized from THF to give 6 as faint yellow crystals, yield 68%; m.p. 200-202˚C. Analytical data; found: C, 53.53; H, 3.31; F, 3.29; N, 18.01%. Calculated for C<sub>24</sub>H<sub>19</sub>FN<sub>7</sub>PO<sub>5</sub>(535); C, 53.83; H, 3.55; F, 3.55; N, 18.31%. IR νcm<sup>−1</sup>: 3425 (NH<sub>2</sub>), 3220-3190 (NH <inline-formula><inline-graphic xlink:href="http://html.scirp.org/file/4-1020331x7.png" xlink:type="simple"/></inline-formula> OH), 1694 (C=O), 1471 (deformation. CH<sub>2</sub>), 1310 (N-N), 1250 (C-F), 1210 (P=O), 1058 (Ph-O-P), 952, 915, 808 (aryl CH).<sup>1</sup>H NMR (DMSO) δ: 12.7, 10.67, 8.8 (each s, 3H, 3NH), 10.24 (s, 1H, OH of pyrazole), 7.66 - 7.400, 7.39-7.00, 6.99-6.79 (each m, 14H, aryl &amp; phenyl protons). <sup>13</sup>C NMR(DMSO) δ:179.54, 163.70, 159.31, 157.74, 134.91, 128.98, 127.31, 123.68, 117.57, 113.29, 113.13, 111.95, 110.69, 110.64, 108.23, 105.08, 104.91, 78.0-77.54.</p><p>3-(3’,5’-Diaminopyrazolin-1’-yl)-6-(5’-fluoro-2’-diphenylphosphorylanilido)-1,2,4-triazin-5(2H)one (7)</p><p>A mixture of 3 (0.01mol) and malononitrile (0.01 mol) in ethanol (50ml) and piperidine (0.5 ml) reflux for 8h, cooled. The solid obtained filtered off and crystallized from ethanol to give 7 as deep orange crystals. Yield 70%; m.p. 205˚C - 207˚C. Analytical data; found: C, 53.55, H, 3.12; F, 3.31; N, 20.71%. Calculated for C<sub>24</sub>H<sub>21</sub>FN<sub>8</sub>PO<sub>4</sub> (535); C, 53.83; H, 3.55; F, 3.55; N, 20.93%. IR: νcm<sup>−1 </sup>3430 - 3380 (NH<sub>2</sub>), 1700 (C=O), 1620 (deform. NH<sub>2</sub>), 1580 (C=N) 1265 (C-F), 1200 (Ph-P=O), 1050 (Ph-O-P), 930, 910, 850, 800(aryl CH).<sup>1</sup>H NMR (DMSO) δ: 12.7, 10.7, 10.2 (each s, 3H, 3NH), 8.8 (s, 1H, NH-P=O), 7.55 - 7.311, 7.131 - 6.991, 6.87 - 6.76 (each m, 14 H, aryl &amp; phenyl protons), 3.89 (s, 4H, 2NH<sub>2</sub>). <sup>13</sup>C NMR (DMSO)δ: 163.73, 159.38, 157.80, 134.93, 127.49, 123.67, 113.38, 113.22, 110.66, 105.18; 105.01, 77.84-77.41, M/S (Int.%): 534 (536, M + 2, 1.55%), 248 (1.11), 97 (3.18) 96 (5.55), 95 (100), 93 (18.11), 68 (42.00), 67 (3.11), 62 (37.15).</p><p>3-(5’-Phenyl-3’-oxo-2,3,4,5-tetrahydro-pyrazolin-1’-yl)-6-(5’-fluoro-2’-diphenyl phosphorylanilido)-1,2, 4-triazin-5-(2H)one(8)</p><p>Equimolar amounts of 3 and cinnamoyl chloride in DMF (20ml) reflux for 4 h, cooled then poured onto ice. The produce solid filtered off and crystallized from dioxan to give 8 as deep yellowish crystals, yield 60%, m.p. 160˚C<sub>.</sub> - 162˚C<sub>. </sub>Analytical data; found: C, 59.89; H, 3.55; F, 3.01; N, 13.75%. Calculated for C<sub>30</sub>H<sub>23</sub>FN<sub>6</sub>PO<sub>5</sub> (597); C, 60.30; H, 3.85; F, 3.18; N, 14.07%. IR νcm<sup>−1</sup>: 3428 (OH), 3180 (NH), 2937 (CH<sub>2</sub>), 1694 (C=0), 1610 (C=N), 1482 (deform. CH<sub>2</sub>), 1314 (N-N), 1230 (C-F), 1169 (P=O), 1059 (Ph-O-P), 954, 909, 809 (aryl CH).<sup>1</sup>H NMR (DMSO) δ: 14.7, 13.5, 12.6 (each s, 3H, 3NH), 10.80 (s, 1H, OH of pyrazole), 8.8 (s, 1H, NH-P=O), 7.99 - 7.41, 7.04 - 7.32, 7.10 - 6.93, 6.88 - 6.40 (each m, 20H, aryl and phenyl protons), 3.23 (s, 2H, NH<sub>2</sub>). <sup>13</sup>C NMR (DMSO) δ: 163.70, 163.58, 162.90, 162.24, 159.34, 157.83, 157.76, 144.07, 134.29, 130.01, 128.77, 127.84, 121.16, 118.94, 118.84, 117.43, 114.23, 113.13, 112.97, 111.94, 111.89, 111.48, 111.43, 110.64, 110.59, 108.30, 108.12, 78.13 - 77.91, 36.26, 31.14.</p><p>3-(3’-(4’’-Nitrophenyl)-5’-(4’’-fluorophenyl)-4’-5’-dihydro-pyrazolin-1’-yl)-6-(5’-fluoro-2’-diphenyl-p- hos-phorylanilido)-1,2,4-triazin-5(2H)one (9)</p><p>A mixture of 3 (0.01 mol) and a chalcone (0.01 mol) in ethanol (50 ml), and piperidine (0.5 ml) reflux for 8 h, cooled then poured on ice-HCl. The solid produce filtered off and crystallized from THF to give 9 as yellow crystals, yield 82%, m.p. 148˚C - 150˚C. Analytical data; found: C, 59.49; H, 3.51; F, 5.21; N, 13.29%. Calculated for C<sub>36</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>PO<sub>6</sub> (721); C, 59.91; H, 3.60; F, 5.27; N, 13.59%. IR νcm<sup>−1</sup>: 3180 (NH), 2827 (CH<sub>2</sub>), 1675 (C=O), 1595 (C=N), 1547 (C=N), 1500, 1423 (deform. CH<sub>2</sub>), 1291 (C-F), 1225 (Ph-P=O), 1097 (Ph-O-P), 921, 847, 762 (aryl CH), 684 (C-Cl). <sup>1</sup>H NMR (DMSO) δ = 10.57, 10.115 (each s, 2H, 2NH), 8.160 - 8.157, (s, 1H, NH-P=O), 8.118 - 8.095, 7.838 - 7.49, 7.23 - 7.010, 6.92 - 6.90, 6.73 - 6.70 (each m, 23H, aryl &amp; phenyl protons) 2.49 - 2.48 (δ, 2H<sub>, </sub>CH<sub>2</sub>). <sup>13</sup>C NMR (DMSO) δ = 163.72, 159.35, 157.78, 134.92, 130.85, 130.80, 129.46, 127.41, 123.86, 123.73, 123.67, 121.10, 113.34, 113.18, 111.98, 110.72, 110.67, 108.09, 107.92, 105.13, 104.97, 77.92 - 77.50, 39.56.</p><p>3-(3’,5’-Dioxo-2’,3’,4’,5’-tetrahydro-pyrazolin-1’-yl)-6-(5’-fluoro-2’-diphenyl phosphorylanilido)-1,2,4- triazin-5’(2H)one (10)</p><p>Equimolar mixture of 3 and diethyl malonate in THF (100 ml) reflux for 8 h, cooled. The solid thus obtain filtered off and crystallized from dioxan to give 10 as faint yellow crystals, yield 66%, m.p. 189-190˚C. Analytical data; found: C, 53.35; H, 3.18; F, 3.35; N, 15.38%. Calculated for C<sub>24</sub>H<sub>18</sub>FN<sub>6</sub>PO<sub>6</sub>(536); C, 53.73; H, 3.35; F, 3.54; N, 15.67%. IR νcm<sup>−1</sup>: 3300 (NH), 3169 (NH), 1694 (C=O), 1626 (C=N), 1579 (C=N), 1471 (deform. CH<sub>2</sub>), 1304 (N-N), 1265 (C-F), 1196 (P=O), 1040 (Ph-O-P), 903, 863, 809 (aryl CH).<sup>1</sup>H NMR (DMSO) δ = 12.7, 10.69, 10.35 (each s, 3H, NH, OH, OH) 9.21 (s, 1H, NH-P=O), 8.15 (s, 1H, C<sub>4</sub> of pyrazole), 7.79 - 7.38, 7.10 - 7.003, 6.99 - 6.79 (each m, 15H, aryl &amp; phenyl protons), 4.18 - 4.17, (δ, CH<sub>2</sub> of pyrazole). <sup>13</sup>CNMR (DMSO) δ = 179.39, 163.58, 162.91, 159.18, 157.61, 134.86, 126.95, 123.74, 123.68, 117.44, 117.28, 113.13, 112.97, 111.94, 110.64, 110.58, 108.12, 107.95, 104.89, 104.72, 78.29 - 77.85, 61.09, 13.94. M/S (Int.%): 536 (538, M + 2, 2.28), 99 (5.5), 96 (13.11), 95 (100), 93 (36.11), 69 (21.85), 68(42.35), 62(5.18).</p><p>3-(5’-Aryl-3’-thioxo-2’,3’-dihydro-1’,2’,4’-triazol-1’-yl)-6-(5’-fluoro-2’-diphenylphosphorylanilido)-1,2,4-triazin-5(2H) one (11)</p><p>A mixture of 3 (0.01 mol) and P-methoxybenzoylisothiocyanate (0.01 mol) in dioxan (20ml) reflux for 4 h, cooled. The solid produce filtered and crystallized from dioxan to give 11 as orange yellowish crystals. Yield 65%, m.p. 141˚C - 192˚C. Analytical data, found: C, 55.62; H, 3.41; F, 2.74; N, 15.02; S, 4.72%. Calculated for C<sub>30</sub>H<sub>23</sub>FNPSO<sub>5 </sub>(643); C, 55.98; H, 3.57; F, 2.95; N, 15.24; S, 4.97%. IR νcm<sup>−1</sup> = 3220-3180 (b, NH), 1693 (C=O), 1624, 1537 (C=N), 1477 (deform. MeO), 1305(N-N), 1266(C-F), 1155 (C-S), 1099 (P=O), 1039(P-O), 980, 840, 809 (aryl CH). <sup>1</sup>H NMR(DMSO) δ = 12.74, 10.80 - 1066, 8.73 (each s, 3H, 3NH), 8.40 - 7.52, 7.38 - 7.30, 7.29 - 7.00, 6.99 - 6.800 (each m, 17H) aryl &amp; phenyl protons), 3.68 - 3.67 (s, 3H, OMe). <sup>13</sup>C NMR(DMSO) δ: 179.64, 163.77, 163.04, 159.40, 158.02, 157.85, 138.58, 134.94, 132.10, 127.60, 123.72, 123.66, 121.13, 121.07, 117.69, 117.53, 113.46, 113.28, 112.02, 110.76, 110.71, 108.10, 107.93, 105.25, 105.07, 77.81 - 77.35, 66.91.</p><p>3-(3’-(4’-Methoxyphenyl)-5’-thioxo-4’,5’-dihydro-1’2’,4’-triazol-1’-yl)-6-(5’-fluoro-2’-diphenylphos p-</p><p>horylanilido)-1,2,4-triazin-5(2H)one (12)</p><p>A mixture of 3 (0.01 mol) and 4-methoxybenzoyl isothiocynate (0.01 mol) is DMF (20 ml) reflux for 4 h, cooled then poured onto ice. The produce solid filtered off and crystallized from ethanol (to give 12 as orange crystals, yield 70%, m.p. 186˚C - 188˚C. Analytical data: found: C, 55.69; H, 3.55; F, 2.70; N, 14.89; S, 4.79%. Calculated for C<sub>30</sub>H<sub>23</sub>FN<sub>7</sub>PSO<sub>5</sub> (643); C, 55.98; H, 3.57; F, 2.95; N, 15.24; S, 4.97%. IR νcm<sup>−1</sup>: 3382 (NH), 3318 (NH), 3204 (NH), 1684 (C=O), 1562 (C=N), 1484 (deform. MeO), 1311 (N-N), 1270 (C-F), 1169 (C=S), 1041 (Ph-O-P), 995, 881, 807 (aryl CH).</p><p>3-Methyl-1H-7-(5’-fluoro-2’-diphenyl phosphorylanilido)-1,2,4-triazino[4,3-b][1,2,4] triazin-4,8-dione (13)</p><p>A mixture of 3 (0.01 mol) and sodium pyruvate (0.01 mol) in sodium hydroxide solution (5%, 100 ml) warm under reflux for 2 h, cooled them poured onto ice HCl. The solid thus obtained filtered off and crystallized 70%, m.p. 220˚C - 222˚C. Analytical data; found: C, 55.19; H, 3.31; F, 3.38; N, 15.88%. Calculated for C<sub>24</sub>H<sub>18</sub>FN<sub>6</sub>PO<sub>5</sub> (520); C, 55.38; H, 3.46; F, 3.65; N, 15%. IR νcm<sup>−1</sup>: 3380, 3162 (NH, NH) 1683 (C=O), 1589, 1553 (C=N), 1458 (deform. CH<sub>3</sub>), 1308 (N-N), 1250 (C-F), 1204 (P=O), 1040 (Ph-O-P), 909, 861, 804 (aryl CH). <sup>1</sup>H NMR (DMSO) δ: 14.55, 12.8 (each s, 2H, 2NH), 10.06 (s, 1H, NH), 7.66 - 7.40, 7.35 - 7.26, 6.93 - 6.76 (each m, 13H, aryl &amp; phenyl protons), 5.58 (s, 1H, OH), 1.256 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR(DMSO)δ:177.40, 176.13, 158.14, 139.40, 128.24, 119.11, 118.95, 118.82, 117.83, 114.59, 114.43, 114.35, 114.29, 112.36, 112.19, 112.09, 112.04, 111.84, 111.77, 111.60, 110.87, 109.95, 109.90, 108.90, 108.37, 77.67 - 77.24, 55.38, 17.21.</p><p>Indolo[3,4-e][1,2,4] triazino [4,3-b]-1,2,4-triazin-11-one (14)</p><p>Equimolar amounts of 3 and isatin in DMF (20 ml) reflux for 2h, cooled then poured onto ice. The yielded solid filtered off and crystallized from dioxan to give 14 as deep-brown crystals, yield 80%, m.p. 198-200˚C. Analytical data found: C, 59.89; H, 3.01; F, 2.98; N, 16.59%. Calculated for C<sub>29</sub>H<sub>19</sub>FN<sub>7</sub>PO<sub>4 </sub>(579); C, 60.10; H, 3.28; F, 3.28, N, 16.92%. IR νcm<sup>−1</sup>: 3139 (NH), 1694 (C=O), 1626, 1540 (C=N), 1305 (N-N), 1250 (C-F), 1157 (P=O), 1080 (Ph-O-P), 970, 900, 850, 811 (aryl CH).<sup>1</sup>H NMR(DMSO) δ=10.76-10.61 (s, 1H, NH), 8.011 (s, 1H, NH-P=O), 7.67 - 7.28, 7.27 - 7.12, 7.05 - 6.94, 6.87 - 6.816 (each m, 17H, aryl and phenyl protons). <sup>13</sup>CNMR (DMSO) δ: 163.77, 163.68, 162.45, 159.48, 157.32, 141.29, 136.82, 134.95, 95.133.65, 130.07, 122.27, 120.80, 120.30, 117.73, 117.57, 113.54, 113.50, 113.38, 112.10, 112.04, 110.79, 110.73, 108.09, 107.92, 105.34, 105.17, 77.67 - 77.24. M/Z (Int. %) 579 (581, M + 2; 13.15%) 331 (31.88), 275 (75.19), 248 (1.15); 141 (18.20), 95 (100), 93 (20.51), 63 (5.13).</p><p>3-Phenyl-1,2,3,4-tetrahydro-7-(5’-fluoro-2’-diphenyl phosphorylanilido)-1,2,4-triazino [4,3-b] [1,2,4] triazin- 8-one (15)</p><p>A mixture of 3 (0.01 mol) and phenacyl bromide (0.01 mol) in ethanolic KOH (5%, 20 ml) reflux for 2 h, then poured onto ice-HCl. The solid produced filtered off and crystallized from THF to give 15 as brownish crystals. Yield 65% m.p., 98˚C - 100˚C. Analytical data; Found: C, 59.98; H, 3.55; F, 3.20; N, 14.51%. Calculated for C<sub>29&#173;</sub>H<sub>22</sub>FN<sub>6</sub>PO<sub>4</sub> (568); C, 61.26; H, 3.87; F, 3.34; N, 14.78%. IR νcm<sup>−1</sup>: 3158 (NH), 1655 (C=O), 1580 (C=N), 1474 (deform. CH<sub>2</sub>), 1308 (N-N), 1230 (C-F), 1180 (P=O), 1092 (Ph-O-P), 980, 950, 900, 850, 801 (aryl CH).<sup>1</sup>H NMR(DMSO) δ = 12.75 (s, 1H, NH), 10.78 (s, 1H, NH-P=O), 7.84 - 7.55, 7.49 - 7.30, 7.29 - 7.00, 6.99 - 6.79 (each m, 18H, aryl &amp; phenyl protons). 3.4 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (DMSO) δ:179.66, 163.04, 159.62, 158.02, 138.60, 129.51, 129.14, 128.67, 128.45, 128.18, 127.18, 126.89, 126.67, 125.86, 125.44, 123.31, 121.05, 120.20, 117.72, 117.56, 113.90, 113.74, 112.21, 112.13, 112.07, 110.47, 110.04, 108.10, 107.92, 77.72-77.29, 36.62.</p><p>7-(5’-Fluoro-2’-diphenylphophorylanilido)-1,2,3,4-tetrahydro-1,2,4-triazino[4,3-b][1,2,4]triazin-4,8-dione (16)</p><p>A mixture of 3 (0.01 mol) and monochloroacetic acid (0.01 mol) in DMF (20 ml) reflux for 2 h, cooled then poured onto ice. The solid thus obtained filtered off and crystallized from THF to give 16 as yellowish crystals. Yield 70%, m.p. 165˚C - 167˚C. Analytical data; found: C, 54.01; H, 3.25; F, 3.58; N, 16.31%. Calculated for C<sub>23</sub>H<sub>18</sub>FN<sub>6</sub>PO<sub>5 </sub>(508); C, 54.33; H, 3.54; F, 3.74; N, 16.53%. IR νcm<sup>−1</sup>: 3382 (NH), 3224 (NH), 1685 (C=O), 1590 (C=N), 1477 (deform. CH<sub>2</sub>), 1250 (C-F), 1180 (P=O), 1041 (Ph-O-P), 807, 760 (aryl CH). <sup>1</sup>H NMR (DMSO) δ: 12.97, 10.70, 10.42 (each s, 3H, 2NH, OH), 9.19 (s, 1H, NH-P=O), 7.99 - 7.00, 6.99 - 6.86, 6.85 - 6.79 (each m, 13H, aryl &amp; phenyl protons), 4.33 (s, 2H, CH<sub>2</sub>). <sup>13</sup>C NMR (DMSO) δ = 173.41, 163.77, 163.67, 159.42, 157.84, 157.70, 136.69, 136.04, 121.23, 121.06, 113.87, 113.81, 113.24, 113.08, 111.48, 111.43, 110.966, 110.699, 111.644, 109.28, 107.00, 106.83, 105.02, 104.02, 78.08 - 77.65, 31.22.</p><p>7-(5’-Fluoro-2’-diphenylphosphorylanilido)-1,2-dihydro-1,2,4-triazino [4,3-b][1,2,4] triazin-3,8-dione (17)</p><p>Equimolar mixture of 3 and 1,1-dichloroacetic acid in DMF (20ml) reflux for 2h, cooled then poured onto ice. The yield obtained filtered and crystallized from dioxan to 17 as yellowish crystals. Yield 78%, m.p. 180˚C - 182˚C. Analytical data: found C, 54.03; H, 2.89; F, 3.55; N, 16.31%. Calculated for C<sub>23</sub>H<sub>16</sub>FN<sub>6</sub>PO<sub>5</sub> (506); C, 54.54; H, 3.16; F, 3.75; N, 16.60%. IR νcm<sup>−1</sup>: 3100 (NH), 1791 (C=O), 1655 (C=O), 1590 (C=N), 1547 (C=N), 1295 (N-N), 1235 (C-F), 1158 (P=O), 1094 (Ph-O-P), 984, 865, 830 (aryl CH).<sup>1</sup>H NMR (DMSO) δ: 12.7 (s, 1H, NH), 10.53 (s, 1H, NH-P=O), 9.07 (s, 1H, CH=N), 7.91 - 7.16, 6.92 - 6.81, 6.77 - 6.71 (each m, 13H, aryl &amp; aryl protons). <sup>13</sup>C NMR(DMSO) δ:179.58, 163.82, 163.01, 162.39, 159.50, 157.92, 142.32, 138.56, 136.67, 136.03, 121.28, 121.12, 117.45, 115.59, 115.43, 113.90, 112.13, 111.47, 110.67, 109.50, 109.34, 108.08, 107.91, 107.12, 106.95, 77.88 - 77.45, 66.36.</p><p>7-(5’-Fluoro-2’-diphenylphosphorylanilido)-1,2,3,4-tetrahydro-1,2,4-triazino[4,3-b][4,34]triazin-3,4,8- trione (18)</p><p>A mixture of 3 (0.01 mol) in dry C<sub>6</sub>H<sub>6</sub> treat with oxalyl chloride (0.01 mol) added dropwise then, TEA added drop wise (few drops) then heated under reflux for 2h, cooled. The solid produce filtered off and crystallized from C<sub>6</sub>H<sub>6</sub> to give 18 as deep-yellowish crystals, yields 60%, m.p. 168˚C - 170˚C. Analytical data: found: C, 52.49; H, 2.85; F, 3.51; N, 15.88%. Calculated for C<sub>23</sub>H<sub>16</sub>FN<sub>6</sub>PO<sub>6</sub> (522); C, 52.87; H, 3.06; F, 3.63; N, 16.09%. IR νcm<sup>−1</sup>: 3382, 3319, 3156 (3NH), 1680 (C=O), 1557 (C=N), 1270 (C-F), 1143 (P=O), 1041 (Ph-O-P), 994, 860, 804 (aryl CH).<sup>1</sup>H NMR (DMSO) δ: 14 (s, 1H, NH), 12.9 (s, 1H, NH), 10.8 (s, 1H, NH-P=O) 9.3, 8.50, 8.0 (each s, aryl protons), 7.45, 7.35, 7.039, 7.035, 7.031, 7.02, 6.886, 6.878, 6.870, 6.86 (m, 10H phenyl protons). <sup>13</sup>C NMR (DMSO) δ: 167.31, 163.07, 159.53, 158.95, 129.48, 128.26, 120.21, 118.50, 118.26, 112.38, 112.33, 112.19, 112.14, 77.62 - 77.202. M/Z (Int.%) 522 (525, M + 3, 18.55), 248 (3.15), 96 (23.11), 95 (100), 93 (8.9), 68 (15.0).</p><p>The acid hydrazido derivative 20</p><p>A mixture of 3 (0.01 mol) and oxazolone19 (0.01 mol) in ethanol (50 ml) with H<sub>2</sub>O (20 ml) reflux for 2 h, cooled then poured onto ice. The produced solid filtered off and crystallized from dioxan to give 20 as yellow crystals. Yield 58%, m.p. 155-157˚C. Analytical data; found: C, 59.89, H, 3.55, F, 5.00; N, 13.05%. Calculated for C<sub>37</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>PO<sub>6</sub> (735); C, 60.40; H, 3.80; F, 5.17; N, 13.13%. IR νcm<sup>−1</sup>: 3600 - 3200 (b, OH, NH, NH), 1592 (CONH), 1480 (deform. CH=C), 1240 (C-F), 1170 (P=O), 1050 (Ph-O-P), 850, 752 (aryl CH).</p><p>3-[5’-(4’’-Fluorophenylidene)-3’-phenyl-1’H-6’-oxo-1’,2’,4’-triazin-2’-yl]-6-(5’-fluoro-2’-diphenylphospho- rylanilido)-1,2,4-triazin-5-(2H)one (21)</p><p>Compound 20 (1 mg) and glacial acetic acid (10ml) reflux for 2h, cooled then poured onto ice. The solid thus obtained filtered off and crystallized from ethanol to give 21 as deep yellowish crystals. Yield 80%, m.p. 233˚C - 235˚C, Analytical data; found: C, 61.81; H, 3.49; F, 5.09; N, 13.55%. Calculated for C<sub>37</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>PO<sub>5 </sub>(717); C, 61.92; H, 3.62; F, 5.29; N, 13.66%. IR νcm<sup>−1</sup>: 3192 (NH), 2880, 2810 (aliphatic CH), 1699 (C=O), 1632 (CONH), 1479 (deform. CH=), 1303 (N-N), 1240 (C-F), 1210 (P=O), 1056 (Ph-O-P), 900, 870, 810, 801 (aryl CH).</p><p>6-[5’-fluoro-2’-(diphenylphosphato)aminophenyl]-3,3,3-triphenyl-3-λ<sup>5</sup>-1,2,4,3-triazaphopholino[4,5-b] [1,2,4]triazine-7(8H) one (22)</p><p>A mixture of compound 2 (0.01 mol) and triphenyl phosphine (0.01 mol) in acetonitryl (20ml) warm for 30 min, cooled. The solid obtained filtered off and crystallized from dioxan to give 22 as deep yellow crystals, yield 70%, m.p. 283˚C - 285˚C. Analytical data; found: C, 64.01; H, 4.15; F, 2.39, N, 11.35%. Calculated for C<sub>39</sub>H<sub>31</sub>FN<sub>6</sub>P<sub>2</sub>O<sub>4 </sub>(728); C, 64.28; H, 4.25; F, 2.60; N, 11.53%. IR νcm<sup>−1</sup>: 3300 - 3100 (b, NH, NH), 1694 (C=O), 1620 (C=N), 1307(N-N), 1264 (C-F), 1179 (P=O), 1027 (Ph-O-P), 910, 880, 793, 745 (aryl CH).</p></sec><sec id="s3"><title>3. Results and Discussion</title><p>α-Aminophosphonic acids continue to elicit study due to interest in their biological properties as herbicides [<xref ref-type="bibr" rid="scirp.52328-ref22">22</xref>] , plant growth regulators [<xref ref-type="bibr" rid="scirp.52328-ref23">23</xref>] and most notably those species heaving a direct P-N bond are investigated as transition state analogues of the tetrahedral transition-state involved in peptide hydropysis [<xref ref-type="bibr" rid="scirp.52328-ref24">24</xref>] . Ali et al. [<xref ref-type="bibr" rid="scirp.52328-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.52328-ref26">26</xref>] studied the reactivity of α-amino phosphonates as dipolar ion structure and have type of tautomeric formula due to the higher e-withdrawing of two phenoxy and P=O groups (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Thus, α-aminophosphonate group had</p><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> A possible present formula of the new synthesized isolated systems</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x8.png"/></fig><p>a higher degree of stability towards any attack of reagents, which attribute to presence of differ factors of stability [<xref ref-type="bibr" rid="scirp.52328-ref27">27</xref>] . Phosphorus elements in these systems, was determine by using the spectrophotomeric. The method is based on the development of floated complex of molybdophosphonic acid (MPA) and methylene blue (MB) with N, N’-diphenylbenzamide (DPBA) in toluene and its subsequent dissolution in acetone [<xref ref-type="bibr" rid="scirp.52328-ref28">28</xref>] .</p><p>A series of some new fluorine substituted phosphoryl-amino-1,2,4-trinzines bearing a functionally pyrazole ring have been obtained via cycloaddition and/or cyclocodensation of 3-hydrazino-1,2,4-trinzinone3 with π-ac- ceptor activated carbon atom reagents. In addition, a type of 1,2,4-trinzino [4,3-b] [1,2,4] triazindiones have been also obtained from cyclocondensation of compound 3 with α, β-bifunctional oxygen and halogen compounds in different conditions. The former structures of the new products confirmed from correct elemental analysis and their spectral measurements. Keeping in view the diverse medicinal activities associated with organo-heterocyclilc systems substituted fluorine, phosphorus and 3-thioxo-1,2,4-trinzinone, which intend to construct novel fluorinated substituted phosphoryl amino bearing 1,2,4-triazinone moiety hoping to active additive effects towards their HIV-1 activity.</p><sec id="s3_1"><title>3.1. Chemistry</title><p>The starting material 3-hydrazino-6-(5’-fluoro-2’-diphenylphosphorylanilido)-1,2,4-trizino-5(2H) one (3) obtained from treatment of 6-(5’-fluoro-2’-aminophenyl)-3-thioxo-1,2,4-triazin-5(2H)one (1) with diphenylphosphoryl chloride in DMF to give 6-(5’-fluoro-2’-diphenylphosphorylanilido)-3-thioxo-1,2,4-triazin-5-one (2) followed by hydrozinolysis in boiling ethanol (Scheme 1).</p><p>Recently, the most reactions of activated nitrites take place in basic medium leading to novel heterocyclic systems [<xref ref-type="bibr" rid="scirp.52328-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.52328-ref30">30</xref>] . Similarly, amino-pyrazolyl-1,2,4-triazinano derivatives 4-7 were obtained from the interaction between compound 3 and arylidenecyanoacetic acid (EtOH-piperidine), acetyl acetanilide (DMF), ethyl cyanoacetate (TFH) and/or malono nitrile (EtOH-piperidine) (Scheme 2).</p><p>These reactions are carried out via cycloaddition and/or cyclocondensation reactions [<xref ref-type="bibr" rid="scirp.52328-ref31">31</xref>] (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p><p>It is interested that 3-perhydropyrazo-1-yl-1,2,4-trizinones 8-10 also obtained from the ring closure reaction of compound 3 with cinnmoyl chloride (DMF), chalcone (EtOH-piperidine) and or diethylmalonate (THF) (Scheme 3).</p><p>Formation of 8 may be take place via aroylation then cycloadditon reaction [<xref ref-type="bibr" rid="scirp.52328-ref32">32</xref>] (<xref ref-type="fig" rid="fig4">Figure 4</xref>).</p><p>The greater reactivity of the polyfunctional compound as aroylisothiocynate towards the hydrazino group as bi-nucleophile is presumably due to its favourable location between both carbonyl and thiocarbonyl functional</p><fig-group id="fig3"><label><xref ref-type="fig" rid="fig3">Figure 3</xref></label><caption><title> Formation of compound 4 from compound 3.</title></caption><fig id ="fig3_1"><label></label><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x12.png"/></fig></fig-group><fig id="fig4"  position="float"><label><xref ref-type="fig" rid="fig4">Figure 4</xref></label><caption><title> Formation of compound 8 from compound 3</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x13.png"/></fig><p>groups [<xref ref-type="bibr" rid="scirp.52328-ref33">33</xref>] . Thus, treatment of 3-hydrazino-1,2,4-trizinone 3 with aroylisothiocyanate in boiling non-polar solvent as dioxan yield 3-(5’-aryl-3’-mercapto-1’,2’,4’-triazol-1’-yl)-6-(5’-fluoro-2’-diphenly phosphorylanilido)-1, 2,4-triazin-5(2H)one (11), while that reaction when carried out in DMF, 3-(3’-aryl-5’-mercapto-1’, 2’,4’-tri- azol-1’-yl)-6-(5’-fluoro-2’-di-phenylphosphorylanilido)-1,2,4-trizin-5-(2H) one (12) isolated (Scheme 4). Formation of compounds 11 and 12 starting from compound 3 were outlined in )Scheme 4(.</p><p>Reactivity of α,β-bifunctional carbonyl compounds towards an hydrazino groups arrived us to synthesize new fused heterobicyclic nitrogen systems. Thus, the interaction between compound 3 and sodium pyruvate in warming sodium hydroxide solution afforded 1H-3-methyl-7-aryl-1,2,4-triazino[4,3-b][1,2,4] traizin-4,8-dione (13), while cyclo-condensation of compound 3 with isatinas 1,2-bicarbonyl compound in boiling DMF yield indolo [2,3-e] [1,2,4] trinzino [4,3-b][1,2,4] triazin one (14). Refluxing of 3 with phenacyl bromide in ethanolic KOH furnish the tetrahydro-1,2,4-triazino [4,3-b][1,2,4] triazin-8-one (15) (Scheme 5).</p><p>A large degree of the biological activity is attributed of the nature of substituent’s and a degree of electronic distribution over the active center of the 1,2,4-triazines [<xref ref-type="bibr" rid="scirp.52328-ref34">34</xref>] [<xref ref-type="bibr" rid="scirp.52328-ref35">35</xref>] . Thus, direct nucleophilic displacement of chlorine atoms by nitrogen or other nucleophilic can easily occur if present α-carbonyl groups. Based on these facts, treatment of compound 3 with activated halogen as chloroacetic acid (DMF), dichloroacetic acid (DMF) and or oxalyl chloride (C<sub>6</sub>H<sub>6</sub>/TEA), produce perhydro 1,2,3,4-tetrahydro-1,2,4-triazino [4,3-b] [1,2,4] triazin- 4,8-dione (16); 1,2-dihydro-1,2,4-triazino [4,3-b] [1,2,4] triazin-4,8-dione (17) and 1,2,3,4-tetrahydro-1,2, 4- triazino [4,3-b] [1,2,4] triazin-3,4,8-trione (18) derivatives (Scheme 6).</p><p>In view of interesting results obtained from the reaction of 1,3-oxazolium salts and of 1,3-oxazol-2-one derivatives with hydrazine derivatives[<xref ref-type="bibr" rid="scirp.52328-ref36">36</xref>] , [<xref ref-type="bibr" rid="scirp.52328-ref37">37</xref>] , it was worthwhile to investigate the behavior of oxazolone19 towards hydrazine-derivative. Similarly, 3-hydrazino-6-aryl-1,2,4-triazin-5 (2H) one (3) when react with oxazole derivation 19 in boiling aqueous ethanol, the acid hydrazide derivative 20 isolated. Ring closure reaction of 20 by refluxing with glacial acetic acid afforded 3-(1’H-3-phenyl-5’-arylidene-6’-oxo-1,2,4-triazin-2’-yl-1-6-(5’-fluoro- 2’-diphenylphosphorylanilido)-1,2,4-triazin-5(2H)one(21)Finally,6-[5’-fluoro-2’-(diphenylphosphato)aminoph-enyl]- 3,3,3-triphenyl-3-λ<sup>5</sup>-1,2,4,3-triazaphopholino[4,5-b][1,2,4]triazine-7(8H) one (22) isolated from treat compound 3 with triphenylphosphine in THF (Scheme 7).</p></sec><sec id="s3_2"><title>3.2. Elucidation the Former Structures</title><sec id="s3_2_1"><title>3.2.1. UV Spectra Study</title><p>UV absorption study of the new compounds, synthesize give us a good indication about electronic distribution</p><p>and molecular configuration as possible.In general, all the new compounds record the presence of n-π<sup>*</sup>, n-σ<sup>*</sup>, π-π<sup>*</sup> and σ-σ<sup>*</sup> electronic transition. UV-absorption spectrum of compound 3 as state recorded λ<sub>max</sub> (EtOH) at 346.48 nm, while that of compounds 14 (361.55) and 12 (361.12). A higher value of λ<sub>max</sub> for 14 and 12 than 3 is may be a lack’s of -OH groups (which generate of H-bending (<xref ref-type="fig" rid="fig5">Figure 5</xref>).</p><p>On the other hand, UV absorption spectra of selected compound record a lower λ<sub>max</sub> than compound 3. λ<sub>max</sub> of 10 (330.56) and 18 (317.22) nm. A lower λ<sub>max</sub> of these compounds than the start is may be due to the presence of O-H group, which generate a type of H-bonding. The Keto-enol forms of 10 and 18 led to the inhibition of heteroconjugative, in addition a type of H-bonding which is closed to 1,2,4-triazine moiety (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><fig id="fig5"  position="float"><label><xref ref-type="fig" rid="fig5">Figure 5</xref></label><caption><title> UV-absorbtion data of compound 3 and some prepared compounds</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x18.png"/></fig><fig id="fig6"  position="float"><label><xref ref-type="fig" rid="fig6">Figure 6</xref></label><caption><title> A possible conformer structure of 18 (fused system)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x19.png"/></fig></sec><sec id="s3_2_2"><title>3.2.2. IR-Absorption Study</title><p>The IR absorption spectral data show that most of the new compounds lack’s a band of NH-P=O, which is due to a type of H-bonding present (<xref ref-type="fig" rid="fig6">Figure 6</xref>), while that of these compounds record only NH bond of new 1,2, 4-triazinones and/or pyrazoles moiety. In addition, IR absorption spectra of all the synthesized compounds exhibit an absorption bands at 3300 - 3190 (NH), 1690 - 1650 (C=O). Moreover presence of a characteristic bands at ν 1390 - 1370 for cyclic NCN, 1250 and 1220 - 1200 cm<sup>−1</sup> for C-F and P=O functional. Also, all the new compounds record ν at 1100 - 1050 cm<sup>−1</sup> attribute to Ph-O-P group. Only, the compounds 3, 4, 6, and 7 record a ν for NH<sub>2</sub> at 3390 - 3400 cm<sup>−1</sup>, while that of the compounds 4, 6, 8, 10, 13, 16-21 showed ν for C=O in addition the original C=O of 1,2,4-trinzine. Finally, IR spectra of the compounds 4, 5, 6, 8-13 and 15, 16 record a type of bands characteristic for aliphatic groups (deformation 1480 - 1440 cm<sup>−1</sup>).</p></sec><sec id="s3_2_3"><title>3.2.3. NMR Spectral Study</title><p>1) <sup>1</sup>H NMR Spectral Study</p><p>The NH proton signals in all the new compounds appear as doublets at δ 8.8 - 8.2 ppm (JP-N-H=6 - 5.5 H<sub>z</sub>) is due to its coupling with phosphorus. Also, H-bonding with oxygen of P=O and the deshielding effect of phenoxyphosphoryl group (Ph-O-P=O) are obviously the contributing factors for the downfield shift of the NH proton. On the other hand, phenoxy protons resonated at δ 7.50 - 7.1 ppm and their integration corresponds to five protons with no splitting of the signals. This shows that all the protons as magnetically equivalent. Normally, exo and endo NH protons of 1,2,4-triazinone reveal at δ12 - 11 ppm, while what of the 1,2,4-tiazinone addujent of CH<sub>2</sub> or NH protons show as enolic protons at δ11 - 10 ppm (5,7,17,18,9).In addition, all the new compounds 4 &amp; 6, exhibited a resonated signals at δ5 - 4 ppm as NH<sub>2</sub> protons and NH proton at δ11 - 10 ppm. Finally, the perhydro pyrazolyl-1,2,4-triazinones and the 1,2,4-trinzino-1,2,4-trinzinones which containing an aliphatic protons show a resonated signals at δ4 - 3 and 1 - 0.5 ppm for CH<sub>2</sub> and CH<sub>3</sub> protons.</p><p>2) <sup>13</sup>CNMR Spectral Study</p><p>The <sup>13</sup>C Chemical shifts of phenoxy moiety are agreeing well with the reported values [<xref ref-type="bibr" rid="scirp.52328-ref38">38</xref>] . But, the coupling constants for <sup>2</sup>Jare concurring with those of equationally oriented P-O-Ar groups [<xref ref-type="bibr" rid="scirp.52328-ref39">39</xref>] showing the 1,2,4-trinzine ring has probably half chair conformation with phosphorus atom projecting upwards and the O-Ar group orienting equationally. The carbons C, which are connected to phosphorous through NH, resonated at δ 112.97 with <sup>2</sup>J P-N-C (d, J 8.1) and the difference in their chemical shifts may be attributed to the variation of shielding effect of NH [<xref ref-type="bibr" rid="scirp.52328-ref40">40</xref>] . In addition, all the new compounds record the resonated attribute to C=O (170 - 160), C-F (150 - 140), C=N(140 - 130), C-N (111 - 110) of 1,2,4-triazinone, with a differ type of carbons of pyrazolyl as well as carbons of other 1,2,4-triazine formed (<xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig8">Figure 8</xref>).</p></sec><sec id="s3_2_4"><title>3.2.4. Mass Spectrometric Measurements</title><p>The mass spectral investigations of the isolated heterobicyclic system is differ than the fused heterobicyclic systems (14 &amp; 18) for example, M/Z of 7 and/or 10 recorded the molecular ion Peak’s at m/z 534 and 336 respectively with a lower abounds percent’s, which indicating the fragile nature of these systems. While M/Z of compound 14 showed the highest value peak at 579 with a base peak at m/z 95, which give us a high degree of stability for this Skelton. Moreover, M/Z of 18 exhibits a molecular ion peak at m/z 522 with moderate abounds percent. From these data, we can conclude that fused heterobicyclic nitrogen systems are more stabilized [<xref ref-type="bibr" rid="scirp.52328-ref41">41</xref>]</p><fig id="fig7"  position="float"><label><xref ref-type="fig" rid="fig7">Figure 7</xref></label><caption><title> <sup>13</sup>C NMR data of compound 10</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x20.png"/></fig><p>than other isolated heterobicyclic systems. It’s interest that in all mass fragmentation pattern, 4-fluorophenyl ion is a base peak followed by N-phosphorus oxide ions, while that heterocycle supported that a large fragmentation bath way (Figures 9-12).</p><fig id="fig8"  position="float"><label><xref ref-type="fig" rid="fig8">Figure 8</xref></label><caption><title> <sup>13</sup>C NMR data of compound 18</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x21.png"/></fig><fig id="fig9"  position="float"><label><xref ref-type="fig" rid="fig9">Figure 9</xref></label><caption><title> Mass Fragmentation pattern of compound 7</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x22.png"/></fig><fig id="fig10"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref>0</label><caption><title> Mass Fragmentation pattern of compound 10</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x23.png"/></fig></sec></sec></sec><sec id="s4"><title>4. HIV-1 Inhibition (Enzyme Inhibition)</title><p>Human immunodeficiency virus type-1 is the causative agent of acquired immunodeficiency syndrome (AIDS) which is one of the most serious health problems [<xref ref-type="bibr" rid="scirp.52328-ref42">42</xref>] . Since reverse transcriptase (RT) is an essential enzyme for the replication [<xref ref-type="bibr" rid="scirp.52328-ref43">43</xref>] of HIV, it is the most favoured target for the antiviral chemotherapy against HIV infection [<xref ref-type="bibr" rid="scirp.52328-ref44">44</xref>] . 3’-Azido-2’,3’-dideoxythymidine (AZT) [<xref ref-type="bibr" rid="scirp.52328-ref45">45</xref>] and 2’,3’-dideoxyinosine (DDI) [<xref ref-type="bibr" rid="scirp.52328-ref46">46</xref>] , 2’,3’-dideoxycyty- dine (DDC) [<xref ref-type="bibr" rid="scirp.52328-ref47">47</xref>] and 2’,3’-didehydro-3-deoxythymidine (DT4) [<xref ref-type="bibr" rid="scirp.52328-ref48">48</xref>] are the well-known potent nucleoside reverse transcriptase inhibitors clinical use, but unfortunately they produce serious side effects such as bone marrow suppression. The search for a more effective and less toxic agent has brought into focus potent yet structurally different non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) [<xref ref-type="bibr" rid="scirp.52328-ref49">49</xref>] . Shakil et al., [<xref ref-type="bibr" rid="scirp.52328-ref50">50</xref>] reported that increase or decrease of electro-negativity and hydrophobicity of the bioactive drugs, cytotoxicity will also increase or decrease accordingly. So less electronegative and less hydrophobic substituents would be preferred to design the less cytotoxic drugs. The large number of research papers published every year indicate that the development of an effective drug for the inhibition of HIV-1 via enzymes inhibitors [<xref ref-type="bibr" rid="scirp.52328-ref51">51</xref>] [<xref ref-type="bibr" rid="scirp.52328-ref52">52</xref>] . HIV PIs for example, prevent the cleavage of the gag and gag-pol precursor polyproteins to the structural proteins and functional proteins, thus arresting maturation and thereby blocking infectivity of the nascent virions. e.g. Tipranavir showed loss cross-resistance to HIV strains that were resistant to the established (peptidomimetic) inhibitors of HIV protease. Also, tipranavir retained marked activity against HIV-1 isolates derived from patients with multidrug resistance to other PIs (<xref ref-type="fig" rid="fig1">Figure 1</xref>3).</p><fig id="fig11"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref>1</label><caption><title> Mass Fragmentation pattern of compound 14</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x24.png"/></fig><p>In search for new poly substituted 1,2,4-triazine bearing a phosphoryl group. The present work is synthesize novel fluorine substituted phosphorylanilido-1,2,4-triazin-ones and evaluate as potential inhibitors for HIV-1. The procedure used in the National Cancer Institute’s Test for agents active against HIV is designed to detect agents acting at any stage of the virus reproductive cycle [<xref ref-type="bibr" rid="scirp.52328-ref53">53</xref>] . The assay basically involves the killing of T<sub>4</sub> lymphocytes by HIV. Small amounts of HIV are added to cells and two cycles of virus reproduction are necessary to obtain the required cell killing. Agents that interact with virions, cells or virus gene-products to inter- fere with viral activities will protect cells from cytolysis. The tetrazolium salt XTT is added to all wells and cultures are incubated to allow formazan color development by viable cells used analyzed spectrophotometrically (<xref ref-type="fig" rid="fig1">Figure 1</xref>4).</p><p>Anti-HIV-1 screening results of some of compounds (<xref ref-type="table" rid="table1">Table 1</xref>) shows that these systems found inactive, probably due to their inability to exist in butterfly like conformation as explained in a similar case [<xref ref-type="bibr" rid="scirp.52328-ref54">54</xref>] . Only the compounds 7, 12, 18 and 22 exhibited a higher protection% (concentration required in protect MT-4 cells against the cytopathogenicity of HIV by 50%). The order reactivity increases as 18 &gt; 10 &gt; 7 &gt; 12 &gt; 22. A higher effect<sup>'</sup>s of compound 18 (<xref ref-type="table" rid="table2">Table 2</xref>) is may be due to a higher possibility to form a type of H-bonds with proteins of virus, which led to a moderate degree of inhibition of HIV-1 activity. Also, compound 18 had a differ type of phenolic bonds, which give a variety of differ effects towards HIV-1 activity. Moreover, compound 18 had a less possibility to form a type of intra-molecular H-bond, thus their hydroxyl group become a higher degree of free action</p><fig id="fig12"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref>2</label><caption><title> Mass Fragmentation pattern of compound 18</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x25.png"/></fig><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The in vitro anti-HIV-1 screening results of new compounds 3-22 in MT-4 cells</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="3"  >Compd. No.</th><th align="center" valign="middle"  rowspan="2"  >Dose (Molar)</th><th align="center" valign="middle"  colspan="4"  >Anti-HIV-1 Activity</th></tr></thead><tr><td align="center" valign="middle" >IC<sub>50</sub> (μg/mL)</td><td align="center" valign="middle" >Max Production %</td><td align="center" valign="middle"  colspan="2"  >Percent of Control</td></tr><tr><td align="center" valign="middle" >2. 00 &#215; 10<sup>−6</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >Infected</td><td align="center" valign="middle" >Uninfected</td></tr><tr><td align="center" valign="middle"  colspan="2"  >3</td><td align="center" valign="middle" >&gt;55.13</td><td align="center" valign="middle" >13.5</td><td align="center" valign="middle" >10.11</td><td align="center" valign="middle" >101.11</td></tr><tr><td align="center" valign="middle"  colspan="2"  >6</td><td align="center" valign="middle" >&gt;20.20</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >17.38</td><td align="center" valign="middle" >106.32</td></tr><tr><td align="center" valign="middle"  colspan="2"  >7</td><td align="center" valign="middle" >&gt;27.20</td><td align="center" valign="middle" >26.5</td><td align="center" valign="middle" >63.51</td><td align="center" valign="middle" >97.93</td></tr><tr><td align="center" valign="middle"  colspan="2"  >10</td><td align="center" valign="middle" >&gt;19. 40</td><td align="center" valign="middle" >30.5</td><td align="center" valign="middle" >80.29</td><td align="center" valign="middle" >96.11</td></tr><tr><td align="center" valign="middle"  colspan="2"  >12</td><td align="center" valign="middle" >&gt;28.57</td><td align="center" valign="middle" >25.0</td><td align="center" valign="middle" >35.40</td><td align="center" valign="middle" >105.77</td></tr><tr><td align="center" valign="middle"  colspan="2"  >14</td><td align="center" valign="middle" >&gt;88.30</td><td align="center" valign="middle" >9.5</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.51</td></tr><tr><td align="center" valign="middle"  colspan="2"  >16</td><td align="center" valign="middle" >&gt;3.99</td><td align="center" valign="middle" >16.00</td><td align="center" valign="middle" >14.16</td><td align="center" valign="middle" >101.91</td></tr><tr><td align="center" valign="middle"  colspan="2"  >18</td><td align="center" valign="middle" >&gt;42.60</td><td align="center" valign="middle" >35.00</td><td align="center" valign="middle" >83.47</td><td align="center" valign="middle" >104.97</td></tr><tr><td align="center" valign="middle"  colspan="2"  >22</td><td align="center" valign="middle" >&gt;94.40</td><td align="center" valign="middle" >23.5</td><td align="center" valign="middle" >18.19</td><td align="center" valign="middle" >104.12</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The in vitro anti-HIV-1 screening results of compound 18</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Index</th><th align="center" valign="middle"  rowspan="2"  >Concentration</th><th align="center" valign="middle"  rowspan="2"  >Dose</th><th align="center" valign="middle"  rowspan="2"  >Percent of Protection</th><th align="center" valign="middle"  colspan="2"  >Percent of Control</th></tr></thead><tr><td align="center" valign="middle" >Infected</td><td align="center" valign="middle" >Uninfected</td></tr><tr><td align="center" valign="middle" >IC<sub>50</sub> (Molar)</td><td align="center" valign="middle" >1.12 &#215; 10<sup>−5</sup></td><td align="center" valign="middle" >6.33 &#215; 10<sup>−9 </sup></td><td align="center" valign="middle" >7.55</td><td align="center" valign="middle" >13.99</td><td align="center" valign="middle" >101.90</td></tr><tr><td align="center" valign="middle" >EC<sub>50 </sub>(Molar)</td><td align="center" valign="middle" >4.26 &#215; 10<sup>−7 </sup></td><td align="center" valign="middle" >2.0 &#215; 10<sup>−8 </sup></td><td align="center" valign="middle" >10.10</td><td align="center" valign="middle" >17.11</td><td align="center" valign="middle" >106.20</td></tr><tr><td align="center" valign="middle" >TIC<sub>50</sub> (IC/E<sub>C</sub>)</td><td align="center" valign="middle" >2.63 &#215; 10<sup>+1 </sup></td><td align="center" valign="middle" >6.35 &#215; 10<sup>−8 </sup></td><td align="center" valign="middle" >12.00</td><td align="center" valign="middle" >18.15</td><td align="center" valign="middle" >104.21</td></tr><tr><td align="center" valign="middle"  colspan="2"   rowspan="5"  ></td><td align="center" valign="middle" >2.00 &#215; 10<sup>−7 </sup></td><td align="center" valign="middle" >30.01</td><td align="center" valign="middle" >32.31</td><td align="center" valign="middle" >105.30</td></tr><tr><td align="center" valign="middle" >6.33 &#215; 10<sup>−7 </sup></td><td align="center" valign="middle" >60.66</td><td align="center" valign="middle" >62.15</td><td align="center" valign="middle" >98.10</td></tr><tr><td align="center" valign="middle" >2.00 &#215; 10<sup>−6 </sup></td><td align="center" valign="middle" >82.23</td><td align="center" valign="middle" >83.47</td><td align="center" valign="middle" >104.99</td></tr><tr><td align="center" valign="middle" >6.34 &#215; 10<sup>−6 </sup></td><td align="center" valign="middle" >75.66</td><td align="center" valign="middle" >80.13</td><td align="center" valign="middle" >99.10</td></tr><tr><td align="center" valign="middle" >2.00 &#215; 10<sup>−5 </sup></td><td align="center" valign="middle" >-7.55</td><td align="center" valign="middle" >0.040</td><td align="center" valign="middle" >0.55</td></tr></tbody></table></table-wrap><fig id="fig13"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref>3</label><caption><title> Tipranavir (PNU-140690)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x26.png"/></fig><fig id="fig14"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref>4</label><caption><title> The standard indicator for HIV present (XXT)</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/4-1020331x27.png"/></fig><p>with a active center of proteins of HIV-1 virus.</p></sec><sec id="s5"><title>5. Conclusion</title><p>In search for new anti-HIV-1, novel fluorine substituted isolated and fused heterobicyclic nitrogen systems bearing 6-(2’-phosphorylanilido)-1,2,4-triazin moiety have been obtained from a ring closure reactions of the corresponding 3-hydrazino-1,2,4-triazinone with π-acceptable reagents. Some compounds exhibited a mark’s inhibitors as anti-HIV-1 activity in hope to a possible control on the HIV-1 activity.</p></sec><sec id="s6"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.52328-ref1"><label>1</label><mixed-citation publication-type="book" xlink:type="simple">Hartley, F.R. and Dahl, O. (1996) The Preparation and Properties of Tervalent Phosphorus Acid Derivatives. In: Brecuer, E. and Heartly, F.R., Eds., The Chemistry of Organophosphorus Compounds: Ter- and Quinque-Valent Phosphorus Acids and Their Derivatives, John Wiley &amp; Sons, New York, 653.</mixed-citation></ref><ref id="scirp.52328-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Prakasha, T.K., Day, R.O. and Holmes, R.R. (1994) Pentacoordinated Molecules. 101. New Class of Bicyclic Oxyphosphoranes with an Oxaphosphorinane Ring: Molecular Structures and Activation Energies for Ligand Exchange. Journal of the American Chemical Society, 116, 8095-8104. http://dx.doi.org/10.1021/ja00097a016</mixed-citation></ref><ref id="scirp.52328-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Fest, C. and Schmidt, K.J. (1982) The Chemistry of Organophosphorus Pesticides. Springer-Verlag, Berlin, 12.http://dx.doi.org/10.1007/978-3-642-68441-8</mixed-citation></ref><ref id="scirp.52328-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bhatia, M.S. and Jit, P. (1976) Phosphorus-Containing Heterocycles as Fungicides: Synthesis of 2,2’-Diphenylene Chlorophosphonate and 2,2’-diphenylene Chlorothiophosphonate. Experienia, 32, 1111. http://dx.doi.org/10.1007/BF01927572</mixed-citation></ref><ref id="scirp.52328-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Manne, P.N., Deshmukh, S.D., Rao, N.G.N., Dodale, H.G., Tikar, S.N. and Nimbalkar, S.A. (2000) Efficacy of Some Insecticides against Helicoverpa armigera (HUB). Pestology, 34, 65.</mixed-citation></ref><ref id="scirp.52328-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Hendlin, D., Stapley, E.O., Jackson, M., Wallick, H., Miller, A.K., Woll, F.J., Miller, T.W., Chaiet, L., Kahan, F.M., Foltz, E.L., Woodruff, H.B., Mata, J.M., Hernandez, S. and Mochales, S. (1969) Phosphonomycin a New Antibiotic Produced by Strains of Streptomyces. Science, 166, 122-123. http://dx.doi.org/10.1126/science.166.3901.122</mixed-citation></ref><ref id="scirp.52328-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Polozov, A.M. and Cremer, S.E. (2002) Synthesis of 2H-1,2-Oxaphosphorin 2-oxides. Journal of Organometallic Chemistry, 646, 153-160. http://dx.doi.org/10.1016/S0022-328X(01)01207-4</mixed-citation></ref><ref id="scirp.52328-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wu, X., Lei, X. and Fu, Z.F. (2003) Rabies Virus Nucleoprotein Is Phosphorylated by Cellular Casein Kinase II. Biochemical and Biophysical Research Communication, 304, 333-338.</mixed-citation></ref><ref id="scirp.52328-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gholivand, K., Shariatinia, Z., Mahzouni, H.R. and Amiri, S. (2007) Phosphorus Heterocycles: Synthesis, Spectroscopic Study and X-Ray Crystallography of Some New Diazaphosphorinanes. Structural Chemistry, 18, 653-660.http://dx.doi.org/10.1007/s11224-007-9197-3</mixed-citation></ref><ref id="scirp.52328-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Page, D.S. (1981) Principles of Biological Chemistry. 2nd Edition, Willard Grant Press, Boston.</mixed-citation></ref><ref id="scirp.52328-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hugcl, H.M. and Jackson, N. (2012) Special Feature Organo-Fluorine Chemical Science. Applied Sciences, 2, 558-565.http://dx.doi.org/10.3390/app2020558</mixed-citation></ref><ref id="scirp.52328-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ismail, F.M.D. (2002) Important Fluorinated Drugs in Experimental and Clinical Use. Journal of Fluorine Chemistry, 118, 27-33. http://dx.doi.org/10.1016/S0022-1139(02)00201-4</mixed-citation></ref><ref id="scirp.52328-ref13"><label>13</label><mixed-citation publication-type="book" xlink:type="simple">Elliott, A.J. (1995) Chemistry of Organic Fluorine Compounds. In: Hudlicky, M. and Pavlath, A.E., Eds., Chemistry of Organic Fluorine Compounds II: A Critical Review, American Chemical Society, Washington DC, 1119-1125.</mixed-citation></ref><ref id="scirp.52328-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Dolbier Jr., W.R. (2005) Fluorine Chemistry at the Millennium. Journal of Fluorine Chemistry, 126, 157-163.http://dx.doi.org/10.1016/j.jfluchem.2004.09.033</mixed-citation></ref><ref id="scirp.52328-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Smart, B.E. (2001) Fluorine Substituent Effects (on Bioactivity). Journal of Fluorine Chemistry, 109, 3-11.http://dx.doi.org/10.1016/S0022-1139(01)00375-X</mixed-citation></ref><ref id="scirp.52328-ref16"><label>16</label><mixed-citation publication-type="book" xlink:type="simple">Ojima, I., McCarthy, J.R. and Welch, J.T., Eds. (1996) Biomedical Frontiers of Fluorine Chemistry. American Chemical Society, Washington DC. http://dx.doi.org/10.1021/bk-1996-0639</mixed-citation></ref><ref id="scirp.52328-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Al-Romaizan, A.N., Abdel-Rahman, R.M. and Makki, M.S.T. (2014) Synthesis of New Fluorine/Phosphorus Substituted 6-(2’-Amino phenyl)-3-thioxo-1,2,4-triazin-5 (2H, 4H) One and Their Related Alkylated Systems as Molluscicidal Agent as against the Snails Responsible for Bilharziasis Diseases. International Journal of Organic Chemistry, 4, 154-168.</mixed-citation></ref><ref id="scirp.52328-ref18"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abdel-Rahman</surname><given-names> R.M. </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Role of Uncondenced1,2,4-triazinecompounds and Related Heterobicyclic Systems as Therapeutic Agents</article-title><source> pharmazie</source><volume> 56</volume>,<fpage> 18</fpage>-<lpage>30</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref19"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abdel-Rahman</surname><given-names> R.M. </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Role of Uncondensed 1,2,4-Triazinederivatives as Biological Plant Protection Agents</article-title><source> Pharmazie</source><volume> 56</volume>,<fpage> 195</fpage>-<lpage>212</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref20"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abdel-Rahman</surname><given-names> R.M. </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>Synthesis and Chemistry of Fluorine Containing 1,2,4-triazines</article-title><source> Pharmazie</source><volume> 54</volume>,<fpage> 791</fpage>-<lpage>804</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref21"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Abdel-Rahman</surname><given-names> R.M. </given-names></name>,<etal>et al</etal>. (<year>2002</year>)<article-title>Synthesis of New Phosphaheterobicyclic Systems Containing 1,2,4-Triazine Moiety Part IX; Straightforward Synthesis of New Fluorine Bearing 5-Phospha-1,2,4-triazin/1,2,4-triazepine-3-thions-part X</article-title><source> Trends in Heterocyclic Chemistry</source><volume> 8</volume>,<fpage> 187</fpage>-<lpage>195</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Treov, K.D. (2006) Chemistry and Application of H-Phosphonates. El-Services, Amsterdam, 256.</mixed-citation></ref><ref id="scirp.52328-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Cherkasov, R.A. and Galki, V.I. (1998) The Kabachnik-Fields Reaction: Synthetic Potential and the Problem of the Mechanism. Russian Chemical Reviews, 67, 857-940. http://dx.doi.org/10.1070/RC1998v067n10ABEH000421</mixed-citation></ref><ref id="scirp.52328-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Annie Bligh, S.W., Mc Grath, C.M., Failla, S. and Finocchiaro, P. (1996) α-Aminophosphate Monoester in One Step. Phosphorus, Sulfured Silicon, 118, 189-194.</mixed-citation></ref><ref id="scirp.52328-ref25"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El-Sayed Ali</surname><given-names> T. </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>Synthesis and Characterization of Novel Bis-(α-Aminophosphonates) with Terminal Chromone Moieties</article-title><source> ARKIVOC</source><volume> 2</volume>,<fpage> 71</fpage>-<lpage>79</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">El-Sayed Ali, T., Abdul-Ghaffar, S.A., El-Mahdy, K.M. and Abdel-Karim, S.M. (2013) Synthesis, Characterization, and Antimicrobial Activity of Some New Phosphorus Macrocyclic Compounds Containing Pyrazole Rings. Turkish Journal of Chemistry, 37, 160-169.</mixed-citation></ref><ref id="scirp.52328-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Abdel-Rahman, R.M. and Ali, T.E. (2013) Synthesis and Biological Evaluation of Some New Polyfluorinated-4- Thiazolidinone and α-Amino Phosphonic Acid Derivatives. Monatshefte fur Chemie, 144, 1243-1252.</mixed-citation></ref><ref id="scirp.52328-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Chakravarty, S. and Mishra, R.K. (1994) Spectrophotometric Determination of Phosphorus with N,N’-Diphenylbenzamidine and Methylen-Blue. Journal of Indian Chemical Society, 71, 717-719.</mixed-citation></ref><ref id="scirp.52328-ref29"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bukowski</surname><given-names> L. </given-names></name>,<etal>et al</etal>. (<year>2001</year>)<article-title>Some Reactions of 2-cyanomethyl-3-methyl-3H-imidazo[4,5-b]pyridine with Isothiocyanates. Antituberculotic Activity of the Obtained Compounds</article-title><source> Pharmazie</source><volume> 56</volume>,<fpage> 23</fpage>-<lpage>27</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Abdel-Rahman, R.M. and Abdel-Monem, W.R. (2007) Chemical Reactivity of 3-Hydrazino-5,6-diphenyl-1,2,4-tri- azine towards π-Acceptors Activated Carbonitriles. Indian Journal of Chemistry, 46B, 838-846.</mixed-citation></ref><ref id="scirp.52328-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Abdel-Rahman, R.M. (1988) Reactions of 3-Hydrazino-5,6-diphenyl-1,2,4-triazine with Unsymmetrical 1,3-bicarbonyl Compounds: Synthesis of Some New 3-(3’,5’-Disubstituted pyrazol-1’-yl(-5-6-diphenyl-1,2,4-triazines of Their Antimicrobial Activity. Indian Journal of Chemistry, 27B, 548-553.</mixed-citation></ref><ref id="scirp.52328-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Zaher, H.A., Abdel-Rahman, R.M. and Abdel-Halim, A.M. (1987) Reactions of 3-Hydrazino-5,6-diphenyl-1,2,4-triazine with α,β-Bifunctional Compounds. Indian Journal of Chemistry, 26B, 110-115.</mixed-citation></ref><ref id="scirp.52328-ref33"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gamal</surname><given-names> A.A. </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>Studies on 3-Amino-1,2,4-triazole</article-title><source> Journal of the Indian Chemical Society</source><volume> 74</volume>,<fpage> 624</fpage>-<lpage>625</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">El-Gendy, Z., Morsy, J.M., Allimony, H.A., Abdel-Monem, W.R. and Abdel-Rahman, R.M. (2001) Synthesis of Heterobicyclic Nitrogen Systems Bearing the 1,2,4-triazine Moiety as Anti-HIV and Anticancer Drugs, Part III. Pharmazie, 56, 376-382.</mixed-citation></ref><ref id="scirp.52328-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">El-Gendy, Z., Morsy, J.M., Allimony, H.A., Abdel-Monem, W.R. and Abdel-Rahman, R.M. (2003) Synthesis of Heterobicyclic Nitrogen Systems Bearing a 1,2,4-Triazine Moiety as Anticancer Drugs, Part IV. Phosphorus, Sulfur and Silicon, 179, 2055-2071. http://dx.doi.org/10.1080/10426500390228738</mixed-citation></ref><ref id="scirp.52328-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Haddadin, M.J. and Hassner, A. (1973) Cycloaddition Reactions. XIV. Thermal and Photochemical Reactions of Some Bicyclic Aziridine Enol Ethers. Journal of Organic Chemistry, 38, 3466-3471. http://dx.doi.org/10.1021/jo00960a005</mixed-citation></ref><ref id="scirp.52328-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Abdel-Rahman, R.M. and El-Gendy, Z. (1989) Synthesis of Some New1,2,4-Benzotriazine Derivatives from 2-Methyl Benzoxazole. Indian Journal of Chemistry, 28B, 1072-1076.</mixed-citation></ref><ref id="scirp.52328-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Buchannan, G.W., Whitman, R.H. and Malaiyandi, M. (1982) A Carbon-13 Nuclear Magnetic Resonance Spectral Investigation of Substituted Triphenyl Phosphates. Organic Magnetic Resonance, 19, 98-101. http://dx.doi.org/10.1002/mrc.1270190211</mixed-citation></ref><ref id="scirp.52328-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Al-Ravi, J.M.A., Behnam, G.O., Naceur, A. and Kruemer, R. (1985) Carbon-13 Chemical Shift Assignment of Some Organophosphorus Compounds. IV—2-oxo- and 2-thio-2-phenoxy-1,3,2-Diazaphosphorinanes and Related P(IV) Com- pounds. Magnetic Resonance in Chemistry, 23,728-731. http://dx.doi.org/10.1002/mrc.1260230910</mixed-citation></ref><ref id="scirp.52328-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Gorenstein, D.G. and Kar, D.J. (1977) Effect of Bond Angle Distortion on Torsional Potentials. Ab Initio and CNDO/2 Calculations on Dimethoxymethane and Dimethyl Phosphate. Journal of the American Chemical Society, 99, 672-677.</mixed-citation></ref><ref id="scirp.52328-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Reddy, C.D., Reddy, G.T. and Reddy, M.S. (1993) 1H,13C and 31P NMR Studies of 2-(Substituted Phenoxy) 2, 3-Di- hydro-1H-Naphtho-[1, 8-de]-1, 3,2-Diazaphosphorine-2-Oxides. Asian Journal of Chemistry, 5, 291-295.</mixed-citation></ref><ref id="scirp.52328-ref42"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clercq</surname><given-names> E.D. </given-names></name>,<etal>et al</etal>. (<year>2002</year>)<article-title>New Developments in Anti-HIV Chemotherapy</article-title><source> Biochemical et Biophysica Acta</source><volume> 1587</volume>,<fpage> 258</fpage>-<lpage>275</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.52328-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Xie, L., Takeuchi, Y., Mark, L. and Lee, K.H. (1999) Anti-AIDS Agents. 37. Synthesis and Structure-Activity Relationships of (3’R,4’R)-(+)-cis-Khellactone Derivatives as Novel Potent Anti-HIV Agents. Journal of Medicinal Chemistry, 42, 2662-20877. http://dx.doi.org/10.1021/jm9900624</mixed-citation></ref><ref id="scirp.52328-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Connoly, K.J. and Hammer, S.M. (1992) Comparative Pharmacokinetics, Distributions in Tissue, and Interactions with Blood Proteins of Conventional and Sterically Stabilized Liposomes Containing 2’,3’-Dideoxyinosine. Antimicrobial Agents and Chemotherapy, 36, 245-254.</mixed-citation></ref><ref id="scirp.52328-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Mitsuya, H., Weinhold, K.J., Fuman, P.A., Clair, M.H., Lehrman, S.N., Gallo, R.C., Bolognesi, D., Barry, D.W. and Broder, S. (1985) 3’-Azido-3’-deoxythymidine (BW A509U): An Antiviral Agent That Inhibits the Infectivity and Cytopathic Effect of Human T-lymphotropic Virus Type III/Lymphadenopathy-Associated Virus in Vitro. Proceedings of the National Academy of Sciences of the United States of America, 82, 709670-707100.</mixed-citation></ref><ref id="scirp.52328-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Mitsuya, H. and Broder, S. (1986) Inhibition of the in Vitro Infectivity Andcytopathic Effect of Human T-Lympho- trophic Virus Type III/Lymphadenopathy-Associated Virus (HTLV-III/LAV) by 2’,3’-dideoxynucleosides. Proceedings of the National Academy of Sciences of the United States of America, 83, 1911-1915. http://dx.doi.org/10.1073/pnas.83.6.1911</mixed-citation></ref><ref id="scirp.52328-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Bozzette, S.A. and Richman, D.D. (1990) Salvage Therapy for Zidovudine-Intolerant HIV-Infected Patients with Alternating and Intermittent Regimens of Zidovudine and Dideoxycytidine. The American Journal of Medicine, 88, S24-S26. http://dx.doi.org/10.1016/0002-9343(90)90418-D</mixed-citation></ref><ref id="scirp.52328-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Dunkel, L., Cross, A., Martin, R., Brown, M. and Murray, H., (1990) Dose-Escalating Study of Safety and Efficacy of Dideoxydidehydrothymidine (d4T) for HIV Infection. Antiviral Research, 13, 116. http://dx.doi.org/10.1016/0166-3542(90)90217-U</mixed-citation></ref><ref id="scirp.52328-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Romero, D.L., Busso, M., Tan, C.K., Reusser, F., Palmer, J.R., Poppe, S.M., Aristoff, P.A., Downey, K.M., So, A.G., Resnick, L. and Tarpley, W.G. (1991) Non-Nucleoside Reverse Transcriptase Inhibitors That Potently and Specifically Block Human Immunodeficiency Virus Type 1 Replication. Proceedings of the National Academy of Sciences of the United States of America, 88, 8806-8810. http://dx.doi.org/10.1073/pnas.88.19.8806</mixed-citation></ref><ref id="scirp.52328-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Srivastava, A.K., Khan, A.A. and Shakil, M. (2001) Quantitative Structure Activity Relationship (QSAR) Studies on Anti-HIV-1 and Cytotoxic Arylpyrrolylsulfones. Journal of the Indian Chemical Society, 78, 154-157.</mixed-citation></ref><ref id="scirp.52328-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Lu, C. and Li, A.P. (2010) Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad. Wiley, OU143, E 605.</mixed-citation></ref><ref id="scirp.52328-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Sergei, V., Gulni, K., Elena, A. and Michael, E. (2010) Enzyme Inhibition in Drug Discovery and Developmental Edited, Lu &amp; Li. Wiley &amp; Sons, Inc., New York, 749.</mixed-citation></ref><ref id="scirp.52328-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Weislow, O.W., Kiser, R., Fine, D., Bader, J., Shoemaker, R.N. and Boyd, M.R. (1989) New Soluble Formazan Assay for HIV-1 Cytopathiceffects, Application to High Flux Screening of Synthetic and Natural Products for AIDS-Anti-viral Activity. Journal of the National Cancer Institute, 81, 577-586. http://dx.doi.org/10.1093/jnci/81.8.577</mixed-citation></ref><ref id="scirp.52328-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Chaouni, B.A., Galtier, C., Allouchi, H., Kherbeche, A., Chavignon, O., Teulade, J.C., Witvrouw, M., Pannecouque, C., Snoeck, R., Andrei, G., Balzarini, J., De Clercq, E., Fauvelle, F., Enguehard, C. and Gueiffier, A. (2001) 3-Benzamido, Ureido and Thioureidimidazo[1,2-a]Pyridine Derivatives as Potential Antiviral Agents. Chemical and Pharmaceutical Bulletin, 49, 1631-1635. http://dx.doi.org/10.1248/cpb.49.1631</mixed-citation></ref></ref-list></back></article>